Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2005

Primary Completion Date

October 12, 2006

Study Completion Date

October 12, 2006

Conditions

Vomiting

Interventions

DRUG

GW679769

GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning

Trial Locations (2)

GSK Investigational Site, Gainesville

GSK Investigational Site, Orlando